Imbria Pharmaceuticals, a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases with high unmet need, today announced the successful closing of a $57.5 million Series B financing with a top-tier syndicate of life science investors led by new investor, Deep Track Capital. Additional new investors participating in the financing include AN Ventures, Catalio Capital Management and Cytokinetics, Inc. Existing investors RA Capital Management and SV Health Investors also contributed to the financing.

Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical pipeline is focused on restoring or improving the cell's ability to produce energy in cardiometabolic disorders where energetic impairment is a fundamental contributor to disease pathogenesis, symptoms and functional deficits. The lead product candidate, ninerafaxstat, has completed multiple Phase 2 clinical trials in three indications: non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and heart failure with preserved ejection fraction (HFpEF). In Phase 1 and 2 clinical trials, ninerafaxstat was shown to be well tolerated.